Literature DB >> 15790704

Differences in growth characteristics and elementary body associated cytotoxicity between Chlamydia trachomatis oculogenital serovars D and H and Chlamydia muridarum.

J M Lyons1, J I Ito, A S Peña, S A Morré.   

Abstract

AIM: In vitro growth and elementary body (EB) associated cytotoxicity of two Chlamydia trachomatis strains belonging to serovars D and H and C muridarum were compared to identify difference(s) that correlate with virulence variations between these strains in the mouse model of human female genital tract infection, and phenotypic characteristics that could explain human epidemiological data on serovar prevalence and levels of shedding during serovar D and H infection.
METHODS: Replication cycle kinetics, inclusion characteristics, and EB associated cytotoxicity were assessed in McCoy cell monolayers using culture, light microscopy, and lactate dehydrogenase release.
RESULTS: Over 72 hours, more rapid production and release of inclusion forming units (ifu) allowed C muridarum to initiate two replication rounds, resulting in 4-8 times more ifu/input unit of infection than with serovars D and H. Although C muridarum EBs were significantly more cytotoxic to McCoy cell monolayers than serovar D at moderate and high multiplicity of infection ratios (MOI), serovar H EBs were significantly more cytotoxic than C muridarum, even at the lowest MOI tested.
CONCLUSIONS: These phenotypic differences are consistent with the more invasive course and severe pathological outcome of infection in mice infected with C muridarum, providing an objective basis for questioning the appropriateness of C muridarum as a surrogate for the human biovar of C trachomatis in the murine model of female genital tract infection. The differences seen between the human strains could help explain human epidemiological data relating to differences in prevalence and level of shedding that occurs during infection with oculogenital serovars D and H.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790704      PMCID: PMC1770636          DOI: 10.1136/jcp.2004.021543

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  29 in total

1.  Analysis of Chlamydia trachomatis serovar distribution changes in the Netherlands (1986-2002).

Authors:  J Spaargaren; I Verhaest; S Mooij; C Smit; H S A Fennema; R A Coutinho; A Salvador Peña; S A Morré
Journal:  Sex Transm Infect       Date:  2004-04       Impact factor: 3.519

2.  Longitudinal assessment of infecting serovars of Chlamydia trachomatis in Seattle public health clinics: 1988-1996.

Authors:  Robert J Suchland; Linda O Eckert; Stephen E Hawes; Walter E Stamm
Journal:  Sex Transm Dis       Date:  2003-04       Impact factor: 2.830

3.  Serovar distribution of urogenital Chlamydia trachomatis strains in The Netherlands.

Authors:  J H Wagenvoort; R J Suchland; W E Stamm
Journal:  Genitourin Med       Date:  1988-06

4.  Purification on renografin density gradients of Chlamydia trachomatis grown in the yolk sac of eggs.

Authors:  L Howard; N S Orenstein; N W King
Journal:  Appl Microbiol       Date:  1974-01

5.  Serotypes of Chlamydia trachomatis in The Gambia.

Authors:  D C Mabey; T Forsey; J D Treharne
Journal:  Lancet       Date:  1987-08-22       Impact factor: 79.321

6.  Immunotypes of Chlamydia trachomatis isolates in Seattle, Washington.

Authors:  C C Kuo; S P Wang; K K Holmes; J T Grayston
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

7.  Asymptomatic sexually transmitted diseases: the case for screening.

Authors:  Thomas A Farley; Deborah A Cohen; Whitney Elkins
Journal:  Prev Med       Date:  2003-04       Impact factor: 4.018

Review 8.  Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses.

Authors:  Irene G M van Valkengoed; Servaas A Morré; Adriaan J C van den Brule; Chris J L M Meijer; Lex M Bouter; A Joan P Boeke
Journal:  Int J Epidemiol       Date:  2004-04       Impact factor: 7.196

9.  Comparison of Chlamydia trachomatis serovars causing rectal and cervical infections.

Authors:  R C Barnes; A M Rompalo; W E Stamm
Journal:  J Infect Dis       Date:  1987-12       Impact factor: 5.226

10.  Cultivation of Chlamydia trachomatis in cycloheximide-treated mccoy cells.

Authors:  K T Ripa; P A Mårdh
Journal:  J Clin Microbiol       Date:  1977-10       Impact factor: 5.948

View more
  18 in total

1.  Recombinant Human Peptidoglycan Recognition Proteins Reveal Antichlamydial Activity.

Authors:  Pavel Bobrovsky; Valentin Manuvera; Nadezhda Polina; Oleg Podgorny; Kirill Prusakov; Vadim Govorun; Vassili Lazarev
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

Review 2.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

Review 3.  Animal models for studying female genital tract infection with Chlamydia trachomatis.

Authors:  Evelien De Clercq; Isabelle Kalmar; Daisy Vanrompay
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

4.  Effect of cold water-induced stress on immune response, pathology and fertility in mice during Chlamydia muridarum genital infection.

Authors:  Tesfaye Belay; Anthony Woart; Vincent Graffeo
Journal:  Pathog Dis       Date:  2017-07-31       Impact factor: 3.166

5.  TLR2, TLR4 and TLR9 genotypes and haplotypes in the susceptibility to and clinical course of Chlamydia trachomatis infections in Dutch women.

Authors:  Stephan P Verweij; Ouafae Karimi; Jolein Pleijster; Joseph M Lyons; Henry J C de Vries; Jolande A Land; Servaas A Morré; Sander Ouburg
Journal:  Pathog Dis       Date:  2015-11-13       Impact factor: 3.166

6.  Dual RNA-seq analysis of in vitro infection multiplicity and RNA depletion methods in Chlamydia-infected epithelial cells.

Authors:  Regan J Hayward; Michael S Humphrys; Wilhelmina M Huston; Garry S A Myers
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

Review 7.  Chlamydia trachomatis vaccine research through the years.

Authors:  Katelijn Schautteet; Evelien De Clercq; Daisy Vanrompay
Journal:  Infect Dis Obstet Gynecol       Date:  2011-06-26

8.  Acquired homotypic and heterotypic immunity against oculogenital Chlamydia trachomatis serovars following female genital tract infection in mice.

Authors:  Joseph M Lyons; Servaas A Morré; Lucy P Airo-Brown; A Salvador Peña; James I Ito
Journal:  BMC Infect Dis       Date:  2005-11-17       Impact factor: 3.090

9.  The CD14 functional gene polymorphism -260 C>T is not involved in either the susceptibility to Chlamydia trachomatis infection or the development of tubal pathology.

Authors:  Sander Ouburg; Joke Spaargaren; Janneke E den Hartog; Jolande A Land; Johan S A Fennema; Jolein Pleijster; A Salvador Peña; Servaas A Morré
Journal:  BMC Infect Dis       Date:  2005-12-20       Impact factor: 3.090

10.  Efficacy of an immune modulator in experimental Chlamydia trachomatis infection of the female genital tract.

Authors:  Joseph M Lyons; James I Ito; Servaas A Morré
Journal:  Infect Dis Obstet Gynecol       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.